Oppenheimer Analysts Give TherapeuticsMD (TXMD) a $14.00 Price Target

TherapeuticsMD (NASDAQ:TXMD) has been assigned a $14.00 price target by stock analysts at Oppenheimer in a note issued to investors on Monday. The brokerage presently has a “buy” rating on the stock. Oppenheimer’s price objective would suggest a potential upside of 155.01% from the company’s previous close.

Other equities research analysts also recently issued research reports about the stock. Cantor Fitzgerald set a $26.00 price target on shares of TherapeuticsMD and gave the stock a “buy” rating in a research note on Monday, July 30th. ValuEngine upgraded shares of TherapeuticsMD from a “hold” rating to a “buy” rating in a research note on Tuesday, May 8th. Zacks Investment Research upgraded shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a research note on Wednesday, May 9th. BidaskClub upgraded shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a research note on Friday, June 8th. Finally, JPMorgan Chase & Co. started coverage on shares of TherapeuticsMD in a research note on Friday, June 15th. They set an “overweight” rating and a $11.00 price target on the stock. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating to the company’s stock. TherapeuticsMD currently has an average rating of “Buy” and an average target price of $14.75.

TXMD opened at $5.49 on Monday. TherapeuticsMD has a fifty-two week low of $4.34 and a fifty-two week high of $7.66. The company has a debt-to-equity ratio of 0.94, a quick ratio of 7.79 and a current ratio of 7.88. The firm has a market cap of $1.21 billion, a price-to-earnings ratio of -14.84 and a beta of 1.53.



TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings results on Monday, July 30th. The company reported ($0.15) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.03). TherapeuticsMD had a negative return on equity of 80.75% and a negative net margin of 582.86%. The business had revenue of $3.80 million for the quarter, compared to analyst estimates of $4.23 million. During the same quarter in the prior year, the firm earned ($0.10) EPS. The firm’s quarterly revenue was down 11.6% on a year-over-year basis. sell-side analysts anticipate that TherapeuticsMD will post -0.6 EPS for the current fiscal year.

Several large investors have recently modified their holdings of the company. Cetera Advisors LLC boosted its stake in shares of TherapeuticsMD by 18.1% in the 1st quarter. Cetera Advisors LLC now owns 57,450 shares of the company’s stock valued at $281,000 after purchasing an additional 8,800 shares in the last quarter. ING Groep NV boosted its stake in shares of TherapeuticsMD by 3.4% in the 1st quarter. ING Groep NV now owns 278,138 shares of the company’s stock valued at $1,355,000 after purchasing an additional 9,176 shares in the last quarter. Swiss National Bank boosted its stake in shares of TherapeuticsMD by 4.0% in the 1st quarter. Swiss National Bank now owns 301,400 shares of the company’s stock valued at $1,468,000 after purchasing an additional 11,600 shares in the last quarter. Iridian Asset Management LLC CT boosted its stake in shares of TherapeuticsMD by 20.3% in the 2nd quarter. Iridian Asset Management LLC CT now owns 68,841 shares of the company’s stock valued at $430,000 after purchasing an additional 11,629 shares in the last quarter. Finally, OppenheimerFunds Inc. boosted its stake in shares of TherapeuticsMD by 0.7% in the 1st quarter. OppenheimerFunds Inc. now owns 1,646,316 shares of the company’s stock valued at $8,017,000 after purchasing an additional 12,236 shares in the last quarter. Institutional investors own 72.13% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

Featured Article: Short Selling Stocks, A Beginner’s Guide

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply